Bioequivalence and Bioavailability Forum 09:31 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

FDA Recommendation on Matrix Effect Determination in CC Assay [Bioanalytics]

posted by Obinoscopy - Nigeria, 2018-10-01 14:38  - Posting: # 19351
Views: 629

Hi Guys,

I am going through the FDA BMV guideline and I noticed they didn't give any specific guidance on how to validate that a Chromatographic Assay method is free from Matrix Effect.

All I saw was this:

"Sponsor should ensure that there are no matrix effect throughout the application of the method"

No detail on how this could be achieved was provided.

For Ligand Binding Assays, they did give some hint on how to evaluate Matrix Effect but no Acceptance Criteria was provided.

Why is this so? Could it be that there are different school of thoughts on how to evaluate matrix effect and the FDA is trying not to take sides?

I personally feel they should have provided a method of evaluating matrix effect. Either they provide that which is in tandem with the EMA or they provide an alternative.

Or what do you think?

Regards,

Scopy

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,929 posts in 4,039 threads, 1,286 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).

As soon as we abandon our own reason, and are content
to rely upon authority, there is no end to our troubles.    Bertrand Russell

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed